Hutchmed Licenses KRAS-Targeted Therapy HMPL-A830 to GSK in Up to $1.295 Billion Deal
Start here
Hutchmed has outlicensed HMPL-A830, a KRAS-targeted ATTC candidate, to GSK. GSK receives exclusive rights to develop and commercialize the candidate worldwide outside Greater China. Hutchmed gets a $110 million upfront payment and is eligible for up to $1.185 billion in development, regulatory and commercial milestone payments, plus tiered sales royalties, bringing the potential total deal value to $1.295 billion. The deal was announced on October 21, 2026. Details on the candidate's clinical stage, trial plans under GSK, and regulatory timelines have not yet been disclosed.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- VBDataPickHutchmed Outlicenses KRAS-Targeted ATTC Candidate HMPL-A830 to GSK for $110 Million Upfront, Up to $1.295 Billion Total
Hutchmed has granted GSK exclusive rights to develop and commercialize the candidate HMPL-A830 worldwide outside Greater China. Hutchmed will receive an upfront payment of $110 million and is eligible for up to $1.185 billion in development, regulatory and commercial milestone payments plus tiered sales royalties, for a potential total deal value of up to $1.295 billion.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 14:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.